Ignite Creation Date:
2024-05-06 @ 7:55 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06181032
Status:
RECRUITING
Last Update Posted:
2024-04-30
First Post:
2023-11-23
Brief Title:
A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies
Sponsor:
First Affiliated Hospital of Fujian Medical University
Organization:
First Affiliated Hospital of Fujian Medical University
Study Overview
Official Title:
A Single-arm Prospective Clinical Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin for the Neoadjuvant Treatment of Biliary Tract Malignancies
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluating the efficacy and safety of adebrelimab in combination with apatinib gemcitabine and cisplatin in the neoadjuvant treatment of patients with biliary tract malignancies
Detailed Description:
Existing immune-combination chemotherapy has shown excellent data in advanced biliary malignancies so what is the efficacy and safety of this regimen in neoadjuvant therapy Moreover the current combination model of immunization combined with anti-angiogenic drugs has become another new direction in the field of solid tumor treatment Therefore our group designed a single-arm prospective clinical study of adebrelimab in combination with apatinib gemcitabine and cisplatin in the neoadjuvant treatment of biliary malignancies aiming at evaluating the efficacy and safety of adebrelimab in combination with apatinib gemcitabine and cisplatin in the neoadjuvant treatment of biliary malignancies in patients with a view to bringing longer-term benefits to patients with resectable biliary malignancies
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None